NLRP3 and age-related macular degeneration: Accordingly, based on the culmination of these data, it is tempting to speculate that compounds such as MCC950 [109], a potent nanomolar direct NLRP3 inhibitor, may serve as promising leads for ML/DHRD therapeutics and possibly sporadic AMD.